New drug combo may boost fertility in women with uterine condition

This study tests whether adding nintedanib, a drug that reduces scarring, to standard hormone therapy can improve live birth rates in women with adenomyosis (a condition where uterine tissue grows into the muscle wall). About 328 infertile women aged 20-38 with frozen embryos will receive either progesterone alone or progesterone plus nintedanib for three months before embryo transfer. The goal is to see if the combination leads to more successful pregnancies.